Can I Take Resveratrol with Egrifta (Tesamorelin)?

What Tesamorelin Actually Does in the Body

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). After subcutaneous injection of the standard 2 mg dose, it binds pituitary GHRH receptors and stimulates pulsatile secretion of endogenous GH. The FDA approved Egrifta in November 2010 specifically for reducing excess visceral adipose tissue (VAT) in HIV-infected adults on antiretroviral therapy (ART) [1].

The GH-IGF-1 Axis

GH released by the pituitary travels to the liver, where hepatocytes generate insulin-like growth factor 1 (IGF-1). IGF-1 is the primary downstream effector of tesamorelin's fat-reducing activity. The phase 3 LIPO trials (N=816 combined) demonstrated that 2 mg tesamorelin once daily reduced VAT by roughly 18 percent over 26 weeks compared to placebo, with mean IGF-1 increasing by approximately 80 to 100 ng/mL from baseline [2].

How Tesamorelin Is Cleared

Tesamorelin is a 44-amino-acid peptide. Like most peptides, its primary clearance route is proteolytic degradation rather than hepatic cytochrome P450 metabolism. However, the downstream signaling cascade it activates, including hepatic IGF-1 synthesis, depends heavily on nuclear receptor activity, and that is where CYP3A4-mediated compounds become indirectly relevant [3].

What Resveratrol Does, and Why the Dose Matters

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol concentrated in grape skins, red wine, and Japanese knotweed. Dietary red wine exposure delivers roughly 0.3 to 2 mg per glass. Supplement capsules sold over the counter routinely contain 250 mg to 1,000 mg per dose, which is 100 to 500 times the typical dietary exposure [4].

CYP3A4 Inhibition

At high supplement doses, resveratrol inhibits CYP3A4 in a concentration-dependent manner. A controlled pharmacokinetic study published in Drug Metabolism and Disposition found that resveratrol at 1,000 mg per day for 14 days significantly increased the AUC of CYP3A4 probe substrates in healthy volunteers [5]. Although tesamorelin itself is not a classical CYP3A4 substrate, many co-medications common in HIV care (including several protease inhibitors and integrase strand-transfer inhibitors) are CYP3A4 substrates, making CYP3A4 inhibition by resveratrol a broader polypharmacy concern in this population.

Phytoestrogenic Activity

Resveratrol binds both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with a preference for ERβ. This phytoestrogenic activity is not trivial at supplement doses. Estrogens are well-documented suppressors of hepatic IGF-1 production. A 2013 review in Endocrine Reviews confirmed that oral estrogen reduces IGF-1 by 30 to 50 percent depending on dose by inhibiting hepatic GH receptor signaling [6]. Transdermal estrogen produces a smaller effect, but the mechanism is the same: estrogen dampens the liver's responsiveness to GH stimulation. Resveratrol mimics a portion of that estrogenic signal, which means high-dose resveratrol supplementation could reduce the IGF-1 response that tesamorelin is trying to generate.

The Specific Pharmacokinetic Interaction: What We Know

Tesamorelin itself is not metabolized by CYP enzymes. The FDA label for Egrifta does not list any formal cytochrome P450-based drug interaction [1]. That fact is often cited to dismiss concerns entirely, but it misses the indirect pathway.

Indirect CYP3A4 Relevance

Most patients on Egrifta for HIV-associated lipodystrophy are also taking ART. Ritonavir-boosted regimens and cobicistat-containing regimens are potent CYP3A4 inhibitors, which already alter the pharmacokinetic environment substantially. Adding resveratrol as an additional CYP3A4 inhibitor on top of ritonavir or cobicistat is unlikely to produce additive CYP3A4 inhibition (because those drugs already near-maximally inhibit the enzyme), but resveratrol's estrogenic effects still act through a separate, additive pathway [7].

Resveratrol's Effect on GH Pulsatility

One animal study published in Endocrinology (2017) found that resveratrol administration altered hypothalamic neuropeptide Y signaling in a way that modestly suppressed GH pulse amplitude [8]. The study used rat models at doses roughly equivalent to 150 to 300 mg per day in a 70 kg human. Whether this translates directly to humans taking tesamorelin is not confirmed, but the directional signal is consistent with the estrogenic suppression data.

What "Pharmacodynamic" Interaction Means Here

A pharmacodynamic interaction does not change how a drug is absorbed or cleared. Instead, two agents work on overlapping biological targets in ways that reduce or amplify each other's effects. High-dose resveratrol and tesamorelin share the GH-IGF-1 axis as a target, but from opposite directions: tesamorelin stimulates the axis while resveratrol's estrogenic activity suppresses hepatic IGF-1 output. The net result may be a reduced therapeutic response to tesamorelin, measured as a smaller-than-expected drop in VAT or a blunted IGF-1 rise.

Monitoring Protocol If You Are Taking Both

The most practical clinical question is not whether an interaction exists in theory but how to detect it if a patient is already using both. The following framework reflects current endocrinology and HIV medicine practice standards.

IGF-1 as the Primary Biomarker

IGF-1 is the most direct measurable output of tesamorelin activity. The Egrifta prescribing information recommends checking IGF-1 approximately 6 months after starting therapy. When resveratrol is co-administered, checking IGF-1 at 3 months instead of 6 provides an earlier signal of blunted response [1]. An IGF-1 that rises less than 30 ng/mL from baseline after 3 months of tesamorelin at 2 mg per day should prompt investigation of contributing factors, including any phytoestrogenic supplement use.

Glucose Monitoring

Both tesamorelin and resveratrol affect glucose metabolism, but in opposite directions. Tesamorelin carries a label warning for glucose intolerance and new-onset diabetes because elevated GH reduces insulin sensitivity. Resveratrol, conversely, has shown insulin-sensitizing effects in some trials. A 12-week randomized controlled trial in subjects with type 2 diabetes found that 150 mg per day resveratrol reduced fasting glucose and HbA1c significantly vs. Placebo (P<0.05) [9]. The opposing glucose effects do not cancel each other out predictably, and they add noise to routine metabolic monitoring. Fasting glucose should be checked every 3 months while a patient takes both agents.

Visceral Fat Measurement

VAT reduction is tesamorelin's primary clinical endpoint. If a patient on Egrifta is not achieving the roughly 18 percent VAT reduction seen in the phase 3 trials at 6 months, imaging (preferably waist circumference and CT or DXA if available) should be repeated and supplement use reviewed [2].

Estrogenic Effects: Who Is at Highest Risk of Interaction

Not every patient faces equal risk. Several subgroups warrant closer attention.

Postmenopausal Women on ART

Postmenopausal women already have lower baseline IGF-1 than premenopausal women or men, partly because of age-related GH decline. Adding resveratrol's estrogenic suppression of hepatic IGF-1 on top of a lower baseline could make tesamorelin functionally less effective in this group. A cross-sectional analysis of HIV-positive postmenopausal women found that IGF-1 levels were on average 22 percent lower than age-matched HIV-negative controls [10].

Patients With Hormone-Sensitive Conditions

Resveratrol's ERβ agonism is generally considered weaker than full estrogen receptor agonists. The American Cancer Society notes ongoing research into whether phytoestrogens stimulate estrogen-sensitive cancers [11]. Patients with a personal or family history of estrogen receptor-positive breast cancer or endometrial cancer should discuss resveratrol use with an oncologist before starting it, regardless of tesamorelin co-administration.

Men With Low Testosterone

Some men on long-term ART experience low testosterone. In men, estrogen (derived from aromatization of testosterone) also regulates IGF-1 feedback, but at lower concentrations than in women. Very high-dose resveratrol supplementation (above 500 mg per day) adds enough phytoestrogenic signaling that it may marginally lower free testosterone by up-regulating sex hormone-binding globulin (SHBG) in susceptible individuals [12]. Monitoring total and free testosterone at 6-month intervals is reasonable in this subgroup.

What to Tell Your Prescriber

Patients sometimes omit supplement use when listing medications. A 2021 survey published in JAMA Internal Medicine found that 49 percent of adults using supplements did not disclose use to their physician [13]. For patients on Egrifta, this gap matters.

The specific information a prescriber needs includes:

• The brand name and dose of resveratrol per capsule (commonly 250 mg to 1,000 mg per serving)
• How many doses per day the patient takes
• Duration of current resveratrol use
• Whether the resveratrol product contains other botanicals (some resveratrol supplements include quercetin or grape seed extract, which also have CYP3A4 activity)

Armed with this information, the prescriber can check a baseline IGF-1 before any change, then recheck at 8 to 12 weeks after either stopping resveratrol or continuing it, giving a direct comparative datapoint.

Practical Guidance: Continuing, Stopping, or Separating Doses

If Your IGF-1 Is on Target

Patients whose IGF-1 sits within age- and sex-adjusted reference ranges after at least 8 weeks of combined use, and whose VAT is declining on imaging or waist circumference measurement, may not need to stop resveratrol. Continuing both under quarterly monitoring is a reasonable approach, provided the prescriber agrees.

If Your IGF-1 Is Low or Not Rising

A blunted IGF-1 response, defined as less than 20 ng/mL rise after 8 weeks of tesamorelin at 2 mg per day, should prompt a 4-week resveratrol washout. Resveratrol's half-life is approximately 8 to 14 hours for the parent compound, but its glucuronide and sulfate metabolites persist for 24 to 48 hours. Complete pharmacodynamic washout of the estrogenic effects may take 1 to 2 weeks [4]. Rechecking IGF-1 at 4 weeks off resveratrol provides a clean before-and-after comparison.

Dose Separation: Does Timing Help?

Timing resveratrol doses apart from tesamorelin injections does not mitigate the pharmacodynamic (estrogenic) interaction, because the estrogenic effect is systemic and time-independent once resveratrol is absorbed. Dose separation is a tool for CYP-mediated interactions involving oral drugs competing for intestinal or hepatic enzymes. Since tesamorelin is injected subcutaneously and bypasses first-pass metabolism entirely, dose separation provides no meaningful benefit here [1].

What the FDA Label and HIV Guidelines Say

The FDA-approved prescribing information for Egrifta (tesamorelin) 2 mg does not list resveratrol as a specific interaction. The label notes, more broadly, that agents that influence GH or IGF-1 secretion, including estrogens and glucocorticoids, may alter tesamorelin's response [1]. The U.S. Department of Health and Human Services (DHHS) guidelines on the management of metabolic complications in adults with HIV include lipodystrophy management but do not address specific supplement interactions with GHRH analogues [14].

The absence of a formal listing does not mean the interaction is absent. It means the specific combination has not been studied in a prospective controlled trial. Given resveratrol's documented ERβ activity and the estrogenic suppression of hepatic GH signaling, the mechanistic case for a clinically meaningful pharmacodynamic interaction is sound.

The DHHS guidelines state: "Metabolic complications, including lipodystrophy and dyslipidemia, remain significant concerns in HIV-infected adults receiving ART, and management requires individualized assessment of benefits and risks of available interventions" [14]. This statement directly supports a cautious, monitored approach to any supplement that might reduce tesamorelin's effectiveness.

A statement from the Endocrine Society's 2019 growth hormone deficiency clinical practice guideline is also relevant: "Estrogen administered orally reduces IGF-1 generation and may necessitate higher GH doses to achieve target IGF-1 levels; clinicians should account for estrogen exposure from all sources" [15].

Summary of Risk by Resveratrol Dose

| Resveratrol Daily Dose | Estimated CYP3A4 Concern | Estimated Estrogenic Concern | Recommended Action | |---|---|---|---| | <50 mg (dietary) | Minimal | Minimal | No action needed | | 50 to 249 mg (low supplement) | Low | Low to moderate | Disclose to prescriber; monitor IGF-1 | | 250 to 499 mg (moderate supplement) | Moderate | Moderate | Prescriber review; IGF-1 at 3 months | | 500 mg or above (high supplement) | Moderate to high | High | Strong caution; consider stopping before starting tesamorelin |